Autolus Therapeutics - ADR opened lower at $1.21, compared with its previous close of $1.24. In the last trading session, the stock traded between $1.17 and $1.24. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Autolus Therapeutics - ADR is now worth
$ 17.70
Resulting in a loss of
$ 82.30 (82.30%)
Note: Past profits do not guarantee future returns.
Rating from 3 Analysts
Today's Change
$-0.04 (-3.24%)
Day High
$1.24
Day Low
$1.17
Day Open
$1.21
Prev Close
$1.24
Volume
24,39,977
1W Return
-12.96%
1M Return
-31.91%
3M Return
-48.95%
6M Return
-24.37%
1Y Return
-20.33%
Market Cap ($ Mn)
318
PE Ratio
-
PB Ratio
8.32
PEG Ratio
-
ROE
-90.54%
ROCE
-42.53%
EPS (TTM)
$-0.15
1 Week
-12.96%
1 Month
-31.91%
3 Months
-48.95%
6 Months
-24.37%
9 Months
-16.43%
Autolus CARLYSLE data show significant lupus score improvements
Longer-term CARLYSLE Phase 1 data presented at ACR Convergence 2026 showed clinically significant improvements in SLEDAI-2K scores. Most patients achieved DORIS, including 100% of those followed for at least six months despite severe baseline disease. Complete renal response was achieved in 66.7% of evaluable patients with lupus nephritis. No ICANS, HLH/IEC-HS, or high-grade CRS events were reported in the safety profile.
2 days agoAutolus Therapeutics to present obe-cel data at ASH 2026 meeting
Autolus Therapeutics presents three abstracts at the ASH Annual Meeting in December 2026. Oral presentation details deepening MRD responses with obe-cel in R/R B-ALL patients. Poster validates qPCR assay concordance with ddPCR for monitoring obe-cel levels. Phase 1 ALARIC trial shows rapid complete haematological response in AL amyloidosis.
8 days agoAutolus Therapeutics grants inducement stock awards to 15 employees
Granted 75,400 stock options and 129,310 RSUs to 15 employees. Stock options priced at $1.66, matching Oct 20, 2026 closing price. Grants issued under 2025 Inducement Plan per Nasdaq Rule 5635(c)(4). Options vest over four years; RSUs vest in four annual installments.
9 days agoFDA grants Autolus RMAT designation for lupus therapy obe-cel
FDA grants RMAT designation to Autolus' obe-cel for SLE and LN. Phase 1 CARLYSLE trial data update due at ACR meeting in Q4 2026. Pivotal Phase 2 LUMINA study enrolling in five countries for refractory LN. Data from LUMINA study expected in 2028.
2mo agoAutolus Therapeutics Q2 Results: Earnings call set for Aug 11
Autolus Therapeutics plc will release its second quarter 2026 financial results and operational highlights before the open of U.S. markets on August 11, 2026. Management will host a conference call and webcast at 8:30am EDT / 1:30pm BST to discuss the financial results and provide a general business update. Participants must pre-register via the company’s website to receive dial-in numbers and personal PINs required for access.
3mo agoAutolus Therapeutics turns gross margin positive, raises FY26 guidance
Autolus Therapeutics reported preliminary Q2 2026 net product revenue of $45 million for AUCATZYL, with gross margins turning positive at 35%. The company raised its FY2026 sales guidance to $140-150 million and secured a $250 million credit facility with Perceptive Advisors.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Autolus Therapeutics - ADR is now worth
$ 17.70
Resulting in a loss of
$ 82.30 (82.30%)
Note: Past profits do not guarantee future returns.
